In the Spotlight...
Pyroptotic cell corpses are crowned with F-actin-rich filopodia that engage CLEC9A signaling in incoming dendritic cells
Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer
Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity
Oxidized mRNA Lipid Nanoparticles for In Situ Chimeric Antigen Receptor Monocyte Engineering
Previous Digests
Rab8a restores youthful function in DCs from aged mice
December 11, 2024
With advanced age comes impaired immunity and thus, increased susceptibility to diseases, including infections and cancer. Investigating factors that contribute to this reduced immune functionality, Singh et al. evaluated splenic and bone marrow-derived DCs and found that in aged...
CD73 and PD-1 gatekeep self-reactive CD4+ T cell expansion
December 4, 2024
T cell tolerance to self antigens is essential for the prevention of autoreactivity, and negative selection in the thymus is partially responsible for this process. However, at least one-third of CD4+ T cells reactive to a self antigen escape...
A tetraspecific NK cell engager armed with IL-2v targets B-NHL
November 27, 2024
To capitalize on the antitumor potential of NK cells for the treatment of B cell non-Hodgkin lymphoma (B-NHL), Demaria et al. developed a clinical-grade tetraspecific NK cell engager (NKCE) that targets NKp46 and CD16a on NK cells and CD2...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
About ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ed Fritsch
Ute Burkhardt
Lauren Hitchings
Gaelle Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Paula Hochman
Shishir Pant
Nathan Suek
Morgan Janes
TESTIMONIALS
I am pleased to voice my support for the mission of ACIR to keep cancer immunotherapy researchers up to date with the current advancements in the field. Given the magnitude of new information emerging from this field, I particularly appreciate their efforts to both identify and highlight the key advancements each week and to distill the new information to key take-away points that can be easily grasped.
Professor of Medicine, Harvard Medical School; Director, MGH Center for Cancer Immunology; Institute Member, Broad Institute of Harvard and MIT
Current Sponsors
